Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 4156075, 10 pages
http://dx.doi.org/10.1155/2016/4156075
Research Article

Metformin Prevents Renal Stone Formation through an Antioxidant Mechanism In Vitro and In Vivo

Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin 300211, China

Received 11 February 2016; Accepted 14 April 2016

Academic Editor: Reiko Matsui

Copyright © 2016 Xiong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Pearle, E. A. Calhoun, and G. C. Curhan, “Urologic diseases in America project: urolithiasis,” Journal of Urology, vol. 173, no. 3, pp. 848–857, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. B. W. Turney, J. M. Reynard, J. G. Noble, and S. R. Keoghane, “Trends in urological stone disease,” BJU International, vol. 109, no. 7, pp. 1082–1087, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Yasui, M. Iguchi, S. Suzuki, and K. Kohri, “Prevalence and epidemiological characteristics of urolithiasis in Japan: National Trends Between 1965 and 2005,” Urology, vol. 71, no. 2, pp. 209–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. S. Milliner, D. M. Wilson, and L. H. Smith, “Phenotypic expression of primary hyperoxaluria: comparative features of types I and II,” Kidney International, vol. 59, no. 1, pp. 31–36, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. S. R. Khan, “Hyperoxaluria-induced oxidative stress and antioxidants for renal protection,” Urological Research, vol. 33, no. 5, pp. 349–357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. L. Hackett, P. N. Shevock, and S. R. Khan, “Madin-Darby canine kidney cells are injured by exposure to oxalate and to calcium oxalate crystals,” Urological Research, vol. 22, no. 4, pp. 197–203, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Kumar, D. Sigmon, T. Miller et al., “A new model of nephrolithiasis involving tubular dysfunction/injury,” Journal of Urology, vol. 146, no. 5, pp. 1384–1389, 1991. View at Google Scholar · View at Scopus
  8. S. R. Khan, “Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations,” The Journal of Urology, vol. 189, no. 3, pp. 803–811, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Y. Li, Y. L. Deng, and B. H. Sun, “Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis,” Urological Research, vol. 37, no. 4, pp. 211–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. H. K. Park, B. C. Jeong, M.-K. Sung et al., “Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin,” The Journal of Urology, vol. 179, no. 4, pp. 1620–1626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-S. Huang, J. Chen, C.-F. Chen, and M.-C. Ma, “Vitamin E attenuates crystal formation in rat kidneys: roles of renal tubular cell death and crystallization inhibitors,” Kidney International, vol. 70, no. 4, pp. 699–710, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. E. L. Schiffrin, “Antioxidants in hypertension and cardiovascular disease,” Molecular Interventions, vol. 10, no. 6, pp. 354–362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. P. Vivekananthan, M. S. Penn, S. K. Sapp, A. Hsu, and E. J. Topol, “Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials,” The Lancet, vol. 361, no. 9374, pp. 2017–2023, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Piwkowska, D. Rogacka, M. Jankowski, M. H. Dominiczak, J. K. Stepiński, and S. Angielski, “Metformin induces suppression of NAD(P)H oxidase activity in podocytes,” Biochemical and Biophysical Research Communications, vol. 393, no. 2, pp. 268–273, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Martin-Montalvo, E. M. Mercken, S. J. Mitchell et al., “Metformin improves healthspan and lifespan in mice,” Nature Communications, vol. 4, article 3192, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. O. Dowling, P. J. Goodwin, and V. Stambolic, “Understanding the benefit of metformin use in cancer treatment,” BMC Medicine, vol. 9, article 33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Ishibashi, T. Matsui, M. Takeuchi, and S. Yamagishi, “Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression,” Hormone and Metabolic Research, vol. 44, no. 12, pp. 891–895, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. I. Morales, D. Detaille, M. Prieto et al., “Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway,” Kidney International, vol. 77, no. 10, pp. 861–869, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Bonnefont-Rousselot, B. Raji, S. Walrand et al., “An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress,” Metabolism: Clinical and Experimental, vol. 52, no. 5, pp. 586–589, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Li and K. E. McMartin, “Strain differences in urinary factors that promote calcium oxalate crystal formation in the kidneys of ethylene glycol-treated rats,” American Journal of Physiology—Renal Physiology, vol. 296, no. 5, pp. F1080–F1087, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. L. Green, M. Hatch, and R. W. Freel, “Ethylene glycol induces hyperoxaluria without metabolic acidosis in rats,” American Journal of Physiology—Renal Physiology, vol. 289, no. 3, pp. F536–F543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. R. Khan, J. M. Johnson, A. B. Peck, J. G. Cornelius, and P. A. Glenton, “Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis,” The Journal of Urology, vol. 168, no. 3, pp. 1173–1181, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. P. Quaile, D. H. Melich, H. L. Jordan et al., “Toxicity and toxicokinetics of metformin in rats,” Toxicology and Applied Pharmacology, vol. 243, no. 3, pp. 340–347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. V. Matveyenko, S. Dry, H. I. Cox et al., “Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin,” Diabetes, vol. 58, no. 7, pp. 1604–1615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Taguchi, A. Okada, H. Kitamura et al., “Colony-stimulating factor-1 signaling suppresses renal crystal formation,” Journal of the American Society of Nephrology, vol. 25, no. 8, pp. 1680–1697, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Tsujihata, C. Momohara, I. Yoshioka, A. Tsujimura, N. Nonomura, and A. Okuyama, “Atorvastatin inhibits renal crystal retention in a rat stone forming model,” Journal of Urology, vol. 180, no. 5, pp. 2212–2217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. R. Khan, “Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis,” Translational Andrology and Urology, vol. 3, no. 3, pp. 256–276, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Itoh, T. Yasui, A. Okada, K. Tozawa, Y. Hayashi, and K. Kohri, “Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis,” The Journal of Urology, vol. 173, no. 1, pp. 271–275, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Taguchi, A. Okada, T. Yasui et al., “Pioglitazone, a peroxisome proliferator activated receptor γ agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats,” The Journal of Urology, vol. 188, no. 3, pp. 1002–1011, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Zuo, A. Khan, P. A. Glenton, and S. R. Khan, “Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L-proline-induced hyperoxaluria in the male Sprague-Dawley rats,” Nephrology Dialysis Transplantation, vol. 26, no. 6, pp. 1785–1796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Joshi, A. B. Peck, and S. R. Khan, “NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 462361, 18 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus